Histologic Evaluation of New Doxycycline Gel Formulation for Subgingival Application in Experimental Periodontitis in Rats

Document Type : Original Article


1 Center for Nanotechnology in Drug Delivery, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Fars, Iran

2 Department of Periodontics, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Fars, Iran


Background and aim: Adjunctive therapy can increase periodontal treatments' success, and to date, various drugs had been suggested. This study aimed to test the efficacy of a new formulation of locally delivered- slow-releasing 10% doxycycline (DOX) gel as a thermogelating system by histologic evaluation in rats with experimental periodontitis.
Materials and methods: Periodontal disease was induced with a ligature in maxillary left and right upper first molars of twenty male Sprague-Dawley rats in a seven-day duration. Left molars were treated with DOX gel while the right ones received vehicle drug in the subgingival area. Animals were randomly divided into two groups (each group contained ten rats). One group received the drug only once, while the second one was treated with twice the drug's application. After seven days, animals were killed and prepared for histologic evaluation.
Results: Application of DOX gel reduced the degree of inflammation, presence of osteoclasts and resorptive lacuna, and the amount of disorientated collagen fibres after one week compared to teeth treated with vehicle drug (p <0.05) after twice application of the drug no adverse effect and necrotic changes were detected in histologic evaluations.
Conclusion: This novel formulation of DOX gel is an effective and safe drug for treating periodontal disease in rats. It seems that the drug can be tested in human clinical trials as an adjunctive treatment for periodontal disease.


Main Subjects

[1]  Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontology 2000. 2004;34(1):9-21.
[2]  Jordan RC. Diagnosis of periodontal manifestations of systemic diseases. Periodontology 2000. 2004;34(1):217-29. https://doi.org/10.1046/j.0906-6713.2002.003433.x.
[3]  Listgarten MA. Structure of the microbial flora associated with periodontal health and disease in man: a light and electron microscopic study. Journal of periodontology. 1976;47(1):1-8. https://doi.org/10.1902/jop.1976.47.1.1.
[4]  Socransky SS. Microbiology of periodontal disease—present status and future considerations. Journal of periodontology. 1977;48(9):497-504. https://doi.org/10.1902/jop.1977.48.9.497.
[5]  Cobb CM. Clinical significance of non‐surgical periodontal therapy: an evidence‐based perspective of scaling and root planing. Journal of Clinical Periodontology. 2002;29:22-32. https://doi.org/10.1034/j.1600-051X.29.s2.4.x.
[6]  Cobb CM. Non‐surgical pocket therapy: Mechanical. Annals of periodontology. 1996;1(1):443-90. https://doi.org/10.1902/annals.1996.1.1.443.
[7]  Suvan JE. Effectiveness of mechanical nonsurgical pocket therapy. Periodontology 2000. 2005;37(1):48-71. https://doi.org/10.1111/j.1600-0757.2004.03794.x.
[8]  Drisko CH. Nonsurgical periodontal therapy. Periodontology. 2001;25:77-88.
[9]  Twetman S. Oral biofilms in health and disease. Annals of the Royal Australasian College of Dental Surgeons. 2016;23:26.
[10] Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranza's clinical periodontology. Elsevier health sciences; 2011.
[11] Pretzl B, Sälzer S, Ehmke B, Schlagenhauf U, Dannewitz B, Dommisch H, Eickholz P, Jockel-Schneider Y. Administration of systemic antibiotics during non-surgical periodontal therapy—A consensus report. Clinical oral investigations. 2019;23(7):3073-85. https://doi.org/10.1007/s00784-018-2727-0.
[12] Southard GL, Godowski KC. Subgingival controlled release of antimicrobial agents in the treatment of periodontal disease. International journal of antimicrobial agents. 1998;9(4):239-53. https://doi.org/10.1016/S0924-8579(98)00004-1.
[13] Aggarwal G, Verma S, Gupta M, Nagpal M. Local Drug Delivery Based Treatment Approaches for Effective Management of Periodontitis. Current Drug Therapy. 2019;14(2):135-52. https://doi.org/10.2174/1574885514666190103112855.
[14] Rams TE, Slots J. Local delivery of antimicrobial agents in the periodontal pocket. Periodontology 2000. 1996;10(1):139-59. https://doi.org/10.1111/j.1600-0757.1996.tb00072.x.
[15] Lang NP, Lindhe J, editors. Clinical periodontology and implant dentistry, 2 Volume Set. John Wiley & Sons; 2015.
[16] D'El Rey-Dantas FT, Feijó LS, Nogueira CE, Curcio BD. Doxycycline: a review regarding properties and clinical use in the equine species. Science and Animal Health. 2018;6(2):101-13.
[17] Riond JL, Riviere JE. Pharmacology and toxicology of doxycycline. Veterinary and human toxicology. 1988;30(5):431.
[18] Hamilton AR, Roberts M, Hutcheon GA, Gaskell EE. Formulation and antibacterial properties of clay mineral-tetracycline and-doxycycline composites. Applied Clay Science. 2019;179:105148. https://doi.org/10.1016/j.clay.2019.105148.
[19] Rawla P, Raj JP. Doxycycline-induced acute pancreatitis: a rare adverse event. Gastroenterology research. 2017;10(4):244. doi: 10.14740/gr838w.
[20] Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical infectious diseases. 1998;26(1):1-10.
[21] Michalova E, Novotna P, Schlegelova J. Tetracyclines in veterinary medicine and bacterial resistance to them. A review. Veterinarni Medicina-UZPI (Czech Republic). 2004.
[22] ALI IBRAHIM ES, Ismail S, Fetih G, Shaaban O, Hassanein K, Abdellah NH. Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application. Acta pharmaceutica. 2012;62(1):59-70. https://doi.org/10.2478/v10007-012-0009-y.
[23] Escobar-Chávez JJ, López-Cervantes M, Naik A, Kalia Y, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. Journal of Pharmacy & Pharmaceutical Sciences. 2006;9(3):339-58.
[24] Shriky B, Kelly A, Isreb M, Babenko M, Mahmoudi N, Rogers S, Shebanova O, Snow T, Gough T. Pluronic F127 thermosensitive injectable smart hydrogels for controlled drug delivery system development. Journal of Colloid and Interface Science. 2020;565:119-30. https://doi.org/10.1016/j.jcis.2019.12.096.
[25] Oshagh M, Heidary S, Nazhvani AD, Koohpeima F, Hosseinabadi OK. Evaluation of histological impacts of three types of orthodontic fixed retainers on periodontium of rabbits. Journal of Dentistry. 2014;15(3):104.
[26] Gupta R, Pandit N, Aggarwal S, Verma A. Comparative evaluation of subgingivally delivered 10% doxycycline hyclate and xanthan-based chlorhexidine gels in the treatment of chronic periodontitis. J Contemp Dent Pract. 2008;9(7):25-32.
[27] Wennström JL, Newman HN, MacNeill SR, Killoy WJ, Griffiths GS, Gillam DG, Krok L, Needleman IG, Weiss G, Garrett S. Utilisation of locally delivered doxycycline in non‐surgical treatment of chronic periodontitis: A comparative multi‐centre trial of 2 treatment approaches. Journal of clinical periodontology. 2001;28(8):753-61. https://doi.org/10.1034/j.1600-051X.2001.280806.x.
[28] Machion L, Andia DC, Lecio G, Nociti Jr FH, Casati MZ, Sallum AW, Sallum EA. Locally delivered doxycycline as an adjunctive therapy to scaling and root planing in the treatment of smokers: A 2‐year follow‐up. Journal of periodontology. 2006;77(4):606-13. https://doi.org/10.1902/jop.2006.050087.
[29] Bogren A, Teles RP, Torresyap G, Haffajee AD, Socransky SS, Wennström JL. Locally delivered doxycycline during supportive periodontal therapy: a 3-year study. Journal of periodontology. 2008;79(5):827-35. https://doi.org/10.1902/jop.2008.070515.
[30] Madi M, Pavlic V, Samy W, Alagl A. The anti-inflammatory effect of locally delivered nano-doxycycline gel in therapy of chronic periodontitis. Acta Odontologica Scandinavica. 2018;76(1):71-6. https://doi.org/10.1080/00016357.2017.1385096.
[31] Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharmaceutical research. 2006;23(12):2709-28. https://doi.org/10.1007/s11095-006-9104-4.
[32] Bezerra MM, Brito GA, Ribeiro RA, Rocha FA. Low-dose doxycycline prevents inflammatory bone resorption in rats. Brazilian Journal of Medical and Biological Research. 2002;35(5):613-6. https://doi.org/10.1590/S0100-879X2002000500015.
[33] Bezerra MM, de Lima V, Alencar VB, Vieira IB, Brito GA, Ribeiro RA, Rocha FA. Selective cyclooxygenase‐2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. Journal of periodontology. 2000;71(6):1009-14. https://doi.org/10.1902/jop.2000.71.6.1009.
[34] Lohinai Z, Benedek P, Fehér E, Györfi A, Rosivall L, Fazekas Á, Salzman AL, Szabó C. Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature‐induced periodontitis in the rat. British journal of pharmacology. 1998;123(3):353-60. https://doi.org/10.1038/sj.bjp.0701604.
[35] Xie R, Kuijpers-Jagtman AM, Maltha JC. Inflammatory responses in two commonly used rat models for experimental tooth movement: comparison with ligature-induced periodontitis. archives of oral biology. 2011;56(2):159-67. https://doi.org/10.1016/j.archoralbio.2010.09.007.
[36] Woutersen RA, Jonker D, Stevenson H, Te Biesebeek JD, Slob W. The benchmark approach applied to a 28-day toxicity study with Rhodorsil Silane in rats: the impact of increasing the number of dose groups. Food and Chemical Toxicology. 2001;39(7):697-707. https://doi.org/10.1016/S0278-6915(01)00015-1.
Volume 2, Issue 4
December 2020
Pages 107-114
  • Receive Date: 07 September 2020
  • Revise Date: 18 October 2020
  • Accept Date: 18 November 2020
  • First Publish Date: 22 November 2020